febit Announces Operational Restructuring
Strategic focus on partnerships with clinical researchers, diagnostic and pharma industry for its microRNA (miRNA) biomarker technology
febit announced a restructuring as a consequence of its strategic focus on blood-based microRNA biomarker discovery, febit’s major business development in 2009/2010, and on partnerships and intellectual property (IP) commercialization. The new focus includes the collaboration and provision of high-end services for clinical researchers in academia, diagnostic companies and the pharma industry. The operational restructuring resulted in a reduction of febit’s workforce by approximately 60 percent.
“The restructuring will allow febit to focus on its most successful business segment at the intersection of nanotechnology and future molecular diagnostics,” said Professor Christof Hettich, chairman of febit’s supervisory board and managing director of febit’s main investor dievini Hopp BioTech holding GmbH & Co. KG. “For biotech technology platform companies, a transition is often difficult and requires a change in management, strategy, and operations. Our decision is based on analysis of a number of factors including what we believe is the best course of action for the company and will also be in the interest of our shareholders.”
As part of the restructuring, Cord F. Staehler, president and CEO, febit, resigned from the executive board and joined Siemens Healthcare. Hartmut Voss, Ph.D., has joined febit as the new co-CEO and will lead the company together with co-CEO Jochen Kohlhaas who will continue to act as febit’s CFO.
Other news from the department business & finance
